Related references
Note: Only part of the references are listed.Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hit
Francesco Cucco et al.
LEUKEMIA (2020)
The double-hit signature identifies double-hit diffuse large B-cell lymphoma with genetic events cryptic to FISH
Laura K. Hilton et al.
BLOOD (2019)
Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium
Andreas Rosenwald et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma
Daisuke Ennishi et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL
Kerry J. Savage et al.
BLOOD (2016)
MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study
Christiane Copie-Bergman et al.
BLOOD (2015)
Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group
Noelia Purroy et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Double hit lymphoma: the MD Anderson Cancer Center clinical experience
Yasuhiro Oki et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
MYC translocation partner gene determines survival of patients with large B-cell lymphoma with MYC- or double-hit MYC/BCL2 translocations
Mette O. Pedersen et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2014)
Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma
Sietse M. Aukema et al.
HAEMATOLOGICA (2014)
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
Shimin Hu et al.
BLOOD (2013)
B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and burkitt lymphoma: study of 39 cases
Anamarija M. Perry et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Dose-Intensive Chemotherapy Including Rituximab in Burkitt's Leukemia or Lymphoma Regardless of Human Immunodeficiency Virus Infection Status Final Results of a Phase 2 Study (Burkimab)
Josep-Maria Ribera et al.
CANCER (2013)
Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study
Carlo Visco et al.
HAEMATOLOGICA (2013)
B-cell Lymphomas With Concurrent IGH-BCL2 and MYC Rearrangements Are Aggressive Neoplasms With Clinical and Pathologic Features Distinct From Burkitt Lymphoma and Diffuse Large B-cell Lymphoma
Matija Snuderl et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2010)
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray
CP Hans et al.
BLOOD (2004)
Share Paper
